Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial

• Published in: Pain and therapy 2022-03, Vol.11 (1), p.241-252
• Main Authors: Zheng, Xiaowei, Ding, Haiying, Xu, Silu, Xie, Ruixiang, Liu, Yuguo, Zhai, Qing, Fang, Luo, Tong, Yinghui, Sun, Jiao, Xin, Wenxiu, Wu, Nan, Chen, Juan, Shi, Wenna, Yang, Ling, Li, Hui, Shao, Jingjing, Wang, Yangkui, Yu, Hui, Zhang, Bo, Du, Qiong, Yang, Yezi, Zhang, Xiaodan, Duan, Cunxian, Zhao, Qiulin, Shi, Jing, Huang, Jing, Fan, Qing, Cheng, Huawei, Chen, Lingya, Kong, Sisi, Zhang, Hui, Gong, Liyan, Zhang, Yiping, Song, Zhengbo, Yang, Yang, Zhou, Shoubing, Huang, Chengsuo, Lin, Jinyuan, Wang, Chenchen, Huang, Xianhong, Wei, Qing, Sun, Yancai, Huang, Ping
• Format: Article
• Language: English
• Subjects: Internal Medicine; Medicine; Medicine & Public Health; Original Research; Pain Medicine
• ISSN: 2193-8237; 2193-651X
• DOI: 10.1007/s40122-021-00342-0

Introduction Opioid-tolerant patients are more likely to deviate from recommended treatments and to experience inadequate analgesia than opioid-naive ones. The aim of this study was to examine whether pharmacist-led management could help improve treatment adherence and quality of life. Methods Eligible patients were randomized in a 1:1 ratio to control group and intervention group. The control group received routine education and support, while the intervention group received additional individualized pharmacist-led care. The primary endpoint was treatment adherence in the per-protocol analysis, as evaluated by blinded assessors. An interim analysis was planned when 30% patients completed the study. Alpha was divided into the interim analysis (0.015) and the final analysis (0.035). Results In the interim analysis (97 and 87 patients in the control and intervention groups, respectively), the primary endpoint was met. Pharmacist-led intervention significantly increased treatment adherence (93.3 vs. 79.8%; OR: 2.25; 95% CI 1.02, 4.94; P  = 0.013), quality of life (0.81 ± 0.17 vs. 0.72 ± 0.25; P  = 0.008), and reporting of adverse events (82.7 vs. 61.9%; OR: 1.88; 95% CI 1.16, 3.07; P  = 0.004). The two groups did not differ in pain control rate (66.7 vs. 57.1%; OR: 1.25; 95% CI 0.87, 1.78; P  = 0.218), breakthrough pain-free rate (66.7 vs. 61.9%; OR: 1.12; 95% CI 0.78, 1.59; P  = 0.532) and pain score (1.97 ± 1.04 vs. 2.15 ± 1.24; P  = 0.522). Conclusions Pharmacist-led management improved treatment adherence, quality of life, and the reporting of adverse events in opioid-tolerant patients with cancer pain. Trial Registration ClinicalTrials.gov, NCT03455023.